SCHEMBL5811642

SCHEMBL5811642

Cc1c(C(=O)NN2CCCCC2)nc(-c2ccccc2Cl)n1-c1ccc(Cl)cc1

nearest known ligand 0.81

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 20/20 0.81
CNR2 P34972 14/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6335080 0.92 CNR1 (0.69) CNR1CNR2
SCHEMBL6337323 0.91 CNR1 (0.81) CNR1CNR2
SCHEMBL675659 0.90 CNR1 (1.00) CNR1CNR2
SCHEMBL4511060 0.90 CNR1 (1.00) CNR1CNR2
SCHEMBL6343724 0.89 CNR1 (0.66) CNR1CNR2
SCHEMBL6340825 0.89 CNR1 (0.81) CNR1CNR2
SCHEMBL4508279 0.88 CNR1 (1.00) CNR1CNR2
SCHEMBL6334895 0.88 CNR1 (0.65) CNR1CNR2
SCHEMBL762432 0.88 CNR1 (1.00) CNR1CNR2
SCHEMBL3692532 0.88 CNR1 (0.82) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006060190-A2 IMIDAZOLE DERIVATIVES BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 WO claimed
WO-2006060203-A2 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DEMENTIA AND RELATED DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 WO claimed
WO-2006060202-A2 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 WO claimed
US-20040248956-A1 Substituted imidazoles as cannabinoid receptor modulators HAGMANN WILLIAM K (US) 2004-12-09 US claimed
EP-1432691-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP claimed
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION 2004-04-01 US claimed
WO-2003063781-A2 SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-08-07 WO claimed
WO-2003040107-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2003-05-15 WO claimed
WO-2006060190-A2 IMIDAZOLE DERIVATIVES BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 WO disclosed
WO-2006060203-A2 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DEMENTIA AND RELATED DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 WO disclosed
WO-2006060199-A2 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 WO disclosed
WO-2006060202-A2 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 WO disclosed
US-20040248956-A1 Substituted imidazoles as cannabinoid receptor modulators HAGMANN WILLIAM K (US) 2004-12-09 US disclosed
WO-2003063781-A2 SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity GPR119, GIPR, PGC CNR1 405/4885CNR2 340/4885
US-20040248956-A1 Substituted imidazoles as cannabinoid receptor modulators CNR1, CNR2, GPR119 CNR1 1/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.